- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02186366
Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type
Study of Abdominal Massage Therapy for Generalized Anxiety Disorder Based on the " Essence Fosters Spirit " Theory
Generalized Anxiety Disorder (GAD) is characterized by the presence of persistent worry or fear of no explicit object and fixed content, or things that might occur in real life,which not corresponds with the realities. Patients with GAD may occur a series of somatic symptoms including muscle tension, backaches, headaches, fatigue, insomnia, restlessness, as well as psychological feelings of anxiety, worry and feeling overwhelmed. And it always brings some type of functional disability or decrease in quality of life. GAD is treated by Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin, Norepinephrine Reuptake Inhibitors(SNRI) and 5-ht1a receptor agonists as regular medication which have the definite effects. But, some adverse reaction of SSRIs or SNRI leads to the compliance of taking medicine of patients with GAD. There is an impressive data suggesting that Abdominal Massage Therapy is effective in decreasing some symptoms of somatic symptoms and psychological feelings.
This study is designed as a parallel group, positive control, non-inferiority study. It will recruit 140 cases of generalized anxiety disorder of deficiency of both heart and spleen type. Both the treatment group and the control group will be randomly assigned 70 cases. Patients in the treatment group will be treated by Abdominal Massage for 6 weeks,and the control group by buspirone . The total study includes 4 views that are respectively before the treatment,after 3 weeks treatment, after the whole treatment , and 3 months after the whole treatment. At all of the 4 views, all participants will be estimated the scores of Hamilton Depression Scale(HAMD) ,self-rating anxiety scale(SAS), and Quality of life assessment scale. At the second, third and the forth views, all participants will be estimated Clinical Global Impression ( CGI). At the first and the third views, all participants will be collected the data of content of hydroxytryptamine(5-HT), Norepinephrine and total cortisol in blood plasma, and of blood stream speed, vascular resistance index and pulsatility index of middle cerebral artery (MCA), anterior cerebral artery(ACA), posterior cerebral artery (PCA) and basilar artery(BA). This study aims to investigate the efficacy of Abdominal Massage Therapy vs. buspirone, and discover the correlation between these scales and these objective indicators.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300193
- Recruiting
- The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
-
Contact:
- Qing Sun, Bachelor
- Phone Number: 13820290606 022-27432580
- Email: gaoshuanger111@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meet criteria for a primary diagnosis of current GAD as demonstrated by a structured clinical interview for Diagnostic and Statistical Manual -IV(DSM-IV);meet a diagnosis of Deficiency of both heart and spleen type.
- The scores of SAS≥50, 24≥the scores of HAMD ≥15.
- The symptoms of anxiety have continued not less than 6months.
Exclusion Criteria:
- major depression, schizophrenia ,bipolar disease other psychotic disorders, drug-dependent persons;
- patients with severe suicidal tendencies;
- women in pregnancy or breastfeeding, menstrual or postpartum recovery;
- suffered from serious illness or impairment of system,such as heart and brain blood vessels, lungs, liver, kidneys and blood system.
- persons allergic to Buspirone and excipient;
- persons suffering from epilepsy or hypertension or Glaucoma or myasthenia gravis or leukopenia;
- persons must be taking monoamine oxidase inhibitors;
- persons who drink a lot;
- persons with the local skin lesions in abdomen damage (such as damage, Burns, etc);
- persons with abdominal visceral tumors, nodules, inflammation, edema, abdominal aortic atherosclerosis;
- persons without the incompetence or unable to read, write and understand independently;
- persons whom the researchers believe should not participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Abdominal Massage Therapy
Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks
|
Buspirone by mouth 5mg three times per day for 6week.
If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
Other Names:
|
Active Comparator: Buspirone
Buspirone by mouth 5mg three times per day for 6week
|
Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks.
If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
reductive rate of Hamilton Depression Scale( HAMD reductive rate)
Time Frame: baseline and post- 6week intervention
|
We will estimate the scores of the Hamilton Depression Scale of participants at baseline and post- 6week intervention,then calculate the HAMD reductive rate according to the following formula:HAMD reductive rate=(scores of HAMD at baseline - scores of HAMD at post- 6week intervention )/ scores of HAMD at baseline×100%
|
baseline and post- 6week intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Scores of Hamilton Depression Scale(HAMD)
Time Frame: baseline, post- 3week intervention, post- 6week intervention and post-3month after 6- week intervention
|
We will estimate the scores of the Hamilton Depression Scale of participants.
|
baseline, post- 3week intervention, post- 6week intervention and post-3month after 6- week intervention
|
Scores of self-rating anxiety scale( SAS)
Time Frame: baseline, post- 3week intervention, post- 6week intervention and post-3month after 6- week intervention
|
We will estimate the scores of the self-rating anxiety scale of participants.
|
baseline, post- 3week intervention, post- 6week intervention and post-3month after 6- week intervention
|
Scores of Quality of life assessment scale
Time Frame: baseline, post- 3week intervention, post- 6week intervention and post-3month after 6- week intervention
|
We will estimate the scores of the Quality of life assessment scale of participants.
|
baseline, post- 3week intervention, post- 6week intervention and post-3month after 6- week intervention
|
Scores of Clinical Global Impression
Time Frame: post- 3week intervention and post- 6week intervention and post-3month after 6- week intervention
|
We will estimate the scores of Clinical Global Impression.
|
post- 3week intervention and post- 6week intervention and post-3month after 6- week intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
content of 5-HT in blood plasma
Time Frame: baseline and post- 6week intervention
|
We will test the content of 5-HT of participants in blood plasma and record the data.
|
baseline and post- 6week intervention
|
content of Norepinephrine in blood plasma
Time Frame: baseline and post- 6week intervention
|
We will test the content of Norepinephrine of participants in blood plasma and record the data.
|
baseline and post- 6week intervention
|
content of total cortisol in blood plasma
Time Frame: baseline and post- 6week intervention
|
We will test the content of total cortisol of participants in blood plasma and record the data.
|
baseline and post- 6week intervention
|
blood stream speed of MCA, ACA, PCA and BA
Time Frame: baseline and post- 6week intervention
|
We will test blood stream speed of MCA, ACA, PCA and BA of patients by Transcranial Doppler and record the data.
|
baseline and post- 6week intervention
|
vascular resistance index of MCA, ACA, PCA and BA
Time Frame: baseline and post- 6week intervention
|
We will test vascular resistance index of MCA, ACA, PCA and BA of patients by Transcranial Doppler and record the data.
|
baseline and post- 6week intervention
|
pulsatility index of MCA, ACA, PCA and BA
Time Frame: baseline and post- 6week intervention
|
We will test pulsatility index of MCA, ACA, PCA and BA of patients by Transcranial Doppler and record the data.
|
baseline and post- 6week intervention
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Disease
- Anxiety Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Receptor Agonists
- Anti-Anxiety Agents
- Buspirone
Other Study ID Numbers
- TECF 20120210
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety Disorders
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
University of MichiganBrain & Behavior Research FoundationRecruitingGeneralized Anxiety Disorder | Anxiety | Social Anxiety Disorder | Panic DisorderUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
Clinical Trials on Buspirone
-
Johns Hopkins Bloomberg School of Public HealthJohns Hopkins University; Massachusetts General Hospital; National Institute... and other collaboratorsCompleted
-
Massachusetts General HospitalBrainCells Inc.CompletedMajor Depressive DisorderUnited States
-
Beijing Union Pharmaceutical Factory LtdR&G Pharma Studies Co.,Ltd.RecruitingGeneralized Anxiety DisorderChina
-
Spaulding Rehabilitation HospitalRecruitingSpinal Cord InjuriesUnited States
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
University of OxfordCompleted
-
Laikο General Hospital, AthensCompleted
-
Nordic Life Science Pipeline Inc.United States Department of DefenseCompleted
-
Northwestern UniversityNational Alliance for Research on Schizophrenia and DepressionCompletedSchizophrenia | Schizoaffective DisorderUnited States